Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Rhea-AI Summary
Nutriband (NASDAQ:NTRB) announced on April 22, 2026 that CEO and co-founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the US fentanyl/opioid crisis, Nutriband’s AVERSA technology and the company’s opportunity to improve safety for easily abused medications.
The episode is available on YouTube, Spotify, iTunes, Amazon Music and jackneel.com for shareholders and interested parties.
Positive
- None.
Negative
- None.
News Market Reaction – NTRB
In the Apr 22 session, NTRB declined 0.24%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Brand naming update | Positive | +2.0% | Selected commercial brand name and outlined AVERSA fentanyl sales potential. |
| Mar 18 | Regulatory approval | Positive | +0.5% | Costa Rica health authority approved kinesiology tapes and AVERSA products. |
| Feb 17 | Distribution agreement | Positive | +4.0% | Signed exclusive Costa Rica distribution deal for AVERSA fentanyl and sports tapes. |
| Jan 30 | Shareholder meeting recap | Positive | +6.0% | Outlined AVERSA development, patents, manufacturing scale-up and regulatory plans. |
| Dec 31 | Shareholder letter | Positive | -3.0% | Summarized 2025 milestones, preferred dividend and AVERSA development outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and strategic updates have often coincided with positive next-day price reactions, with one notable divergence on a shareholder letter.
Over the past several months, Nutriband has advanced its AVERSA abuse-deterrent fentanyl patch and broader product strategy. On Dec 31, 2025, a shareholder letter highlighted a $5M Pocono sale, a 25% preferred stock dividend, and key patents. Subsequent news in early 2026 covered an exclusive Costa Rica distribution deal, regulatory approval for kinesiology tapes there, and, on Mar 30, 2026, selection of a commercial brand name for its lead AVERSA fentanyl patch. Today’s podcast appearance continues this communication and awareness-building trend around AVERSA and the opioid crisis.
Key Terms
fentanyl medical
opioid crisis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company’s AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.
Interested shareholders may find the link to the latest youtube episode here https://youtu.be/HB6E7TxGXqg?si=VU6c57saNbdzxraH.
The Episode can also be found on Spotify, iTunes, Amazon music and www.jackneel.com
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
